Soliqua is a once-daily injection that combines Lantus, or insulin glargine, with lixisenatide. The treatment is intended for adults with type 2 diabetes who cannot control their glycemic levels with basal insulin.
Paris, France-based Sanofi expects Soliqua to hit pharmacy shelves in January 2017.
More articles on supply chain:
6 latest FDA approvals
Bundled payments reach a turning point: Four strategies for success
Gartner names top 25 supply chains in healthcare
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
